Piper Sandler Maintains Overweight on Alkermes, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 63.4%

Neg 63.4% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem maintains Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $45 to $43.